Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.
Schiantarelli J, Pappa T, Conway J, Crowdis J, Reardon B, Dietlein F, Huang J, Stanizzi D, Carey E, Bosma-Moody A, Imamovic A, Han S, Camp S, Kofman E, Shannon E, Barletta JA, He MX, Liu D, Park J, Lorch JH, Van Allen EM. Schiantarelli J, et al. Among authors: shannon e. JCO Precis Oncol. 2022 Aug;6:e2200183. doi: 10.1200/PO.22.00183. JCO Precis Oncol. 2022. PMID: 36075011 Free PMC article. No abstract available.
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM. Keenan TE, et al. Among authors: shannon e. Clin Cancer Res. 2021 Feb 15;27(4):983-991. doi: 10.1158/1078-0432.CCR-20-3089. Epub 2020 Nov 30. Clin Cancer Res. 2021. PMID: 33257427 Free PMC article. Clinical Trial.
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM. Bi K, et al. Among authors: shannon e. Cancer Cell. 2021 May 10;39(5):649-661.e5. doi: 10.1016/j.ccell.2021.02.015. Epub 2021 Mar 11. Cancer Cell. 2021. PMID: 33711272 Free PMC article.
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Keenan TE, et al. Among authors: shannon e. Nat Commun. 2021 Sep 21;12(1):5563. doi: 10.1038/s41467-021-25769-z. Nat Commun. 2021. PMID: 34548479 Free PMC article. Clinical Trial.
Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.
Hoffman SE, Dowrey TW, Villacorta Martin C, Bi K, Titchen B, Johri S, DelloStritto L, Patel M, Mackichan C, Inga S, Chen J, Grimaldi G, Napolitano S, Wakiro I, Wu J, Yeung J, Rotem A, Sicinska E, Shannon E, Clancy T, Wang J, Denning S, Brais L, Besson NR, Pfaff KL, Huang Y, Kao KZ, Rodig S, Hornick JL, Vigneau S, Park J, Kulke MH, Chan J, Van Allen EM, Murphy GJ. Hoffman SE, et al. Among authors: shannon e. Sci Adv. 2023 Sep 29;9(39):eadd9668. doi: 10.1126/sciadv.add9668. Epub 2023 Sep 27. Sci Adv. 2023. PMID: 37756410 Free PMC article.
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Balch SM, Vaz-Luis I, Li T, Tayob N, Jain E, Helvie K, Buendia-Buendia JE, Shannon E, Isakoff SJ, Tung NM, Krop IE, Lin NU, Wagle N, Freedman RA. Balch SM, et al. Among authors: shannon e. Breast Cancer Res Treat. 2021 Sep;189(2):411-423. doi: 10.1007/s10549-021-06329-x. Epub 2021 Jul 24. Breast Cancer Res Treat. 2021. PMID: 34302589 Clinical Trial.
Activation of Tumor-Cell STING Primes NK-Cell Therapy.
Knelson EH, Ivanova EV, Tarannum M, Campisi M, Lizotte PH, Booker MA, Ozgenc I, Noureddine M, Meisenheimer B, Chen M, Piel B, Spicer N, Obua B, Messier CM, Shannon E, Mahadevan NR, Tani T, Schol PJ, Lee-Hassett AM, Zlota A, Vo HV, Ha M, Bertram AA, Han S, Thai TC, Gustafson CE, Venugopal K, Haggerty TJ, Albertson TP, Hartley AV, Eser PO, Li ZH, Cañadas I, Vivero M, De Rienzo A, Richards WG, Abu-Yousif AO, Appleman VA, Gregory RC, Parent A, Lineberry N, Smith EL, Jänne PA, Miret JJ, Tolstorukov MY, Romee R, Paweletz CP, Bueno R, Barbie DA. Knelson EH, et al. Among authors: shannon e. Cancer Immunol Res. 2022 Aug 3;10(8):947-961. doi: 10.1158/2326-6066.CIR-22-0017. Cancer Immunol Res. 2022. PMID: 35678717 Free PMC article.
Ischemic Event Rates in Very-High-Risk Adults.
Colantonio LD, Shannon ED, Orroth KK, Zaha R, Jackson EA, Rosenson RS, Exter J, Mues KE, Muntner P. Colantonio LD, et al. Among authors: shannon ed. J Am Coll Cardiol. 2019 Nov 19;74(20):2496-2507. doi: 10.1016/j.jacc.2019.09.025. J Am Coll Cardiol. 2019. PMID: 31727288 Free article.
Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease.
Muntner P, Orroth KK, Mues KE, Exter J, Shannon ED, Zaha R, Rosenson RS, Jackson EA. Muntner P, et al. Among authors: shannon ed. Cardiovasc Drugs Ther. 2022 Jun;36(3):475-481. doi: 10.1007/s10557-021-07167-1. Epub 2021 Mar 4. Cardiovasc Drugs Ther. 2022. PMID: 33661432 Free PMC article.
170 results